Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer model

Cancer Gene Therapy

Volumn 7, Issue 7, 2000, Pages 1086-1099

  Majumdar, Anish Sen ^a,c   Zolotorev, Alya ^a   Samuel, Sara ^a   Tran, Kimvan ^a   Vertin, Beth ^a   Hall Meier, Melinda ^a   Antoni, Beth Ann ^a   Adeline, Emmanuelle ^b   Philip, Mohan ^a   Philip, Ramila ^a  

^a Discovery Research Group   (United States)

^b Centre de Recherche de Vitry   (France)

^c GERON CORPORATION   (United States)

Author keywords

Breast cancer; Gene therapy; Granulocyte macrophage colony stimulating factor; Herpes simplex virus thymidine kinase; Interleukin 2; Metastasis

Indexed keywords

CYTOKINE; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; THYMIDINE KINASE;

ADENOVIRUS; ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; EXPERIMENTAL NEOPLASM; GENE THERAPY; HERPES SIMPLEX VIRUS; IMMUNOPHENOTYPING; LUNG METASTASIS; LYMPHOCYTIC INFILTRATION; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUICIDE GENE; SURVIVAL; TUMOR REGRESSION;

ADENOVIRIDAE; ANIMALIA; HERPES; SIMPLEXVIRUS;

EID: 0033914768     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700215     Document Type: Article

References (42)

1. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control study. Cancer Res. 1986;46: 5276-5281.
2. Moolten FL. Drug sensitivity (suicide) genes for selective cancer chemotherapy. Cancer Gene Ther. 1994;1:279-287.
3. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of tumor mass is genetically modified. Cancer Res. 1993;53: 5274-5283.
4. Chen SH, Shine HD, Goodman JC, Grossman RG, Woo SL. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated transfer in vivo. Proc Natl Acad Sci USA. 1994;91:3054-3057.
5. Hamel W, Magnelli L, Chiarugi VP, Israel MA. Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res. 1996;56:2697-2702.
6. Elshami AA, Saavedra A, Zhang H, et al. Gap junctions play a role in the "bystander effect" of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 1996;3:85-92.
7. Kianmanesh AR, Perrin H, Panis Y, et al. A "distant" bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor. Hum Gene Ther. 1997;8:1807-1814.
8. Vrionis FD, Wu JK, Qi P, Waltzman M, Cherington V, Spray DC. The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HS-Vtk) gene is dependent on connexin expression and cell communication via gap junctions. Gene Ther. 1997;4:577-585.
9. Ram Z, Walbridge S, Shaewr T, Culver KW, Blaese RM, Oldfield EH. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J Neurosurg. 1994;81:256-260.
10. Barba D, Hardin J, Sadelain M, Gage FH. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA. 1994;91:4348-4352.
11. Gangadeep S, Brew R, Green B, et al. Prodrug-activated gene therapy: involvement of an immunological component in the bystander effect. Cancer Gene Ther. 1996;3:83-88.
12. Vile RG, Castleden S, Marshall J, Camplejohn R, Upton C, Chong H. Generation of an anti-tumor immune response in a non-immunogenic tumor: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a TH1-like profile of intratumoral cytokine expression. Int J Cancer. 1997;71:267-274.
13. Colombo MP, Forni G. Cytokine gene transfer in tumor inhibition and tentative tumor therapy: where are we now? Immunol Today. 1994;15:48-51.
14. Porgador A, Feldman M, Eisenbach L. Immunotherapy of tumor metastases via gene therapy. Nat Immun. 1994;13: 113-130.
15. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst. 1997;89:21-39.
16. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med. 1990;172:1217-1224.
17. Cavallo F, Di Pierro F, Giovarelli M, et al. Protective and curative potential of vaccination with IL-2 gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res. 1993;53:5067-5070.
18. Stoppacciaro A, Melani C, Parenza M, et al. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T-cell-produced interferon-γ. J Exp Med. 1993;178:151-161.
19. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent antitumor activity in vivo. Cell. 1989;57: 503-512.
20. Ganbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated interferon-γ gene transfer into tumor cells generates potent and long-lasting antitumor immunity. Cancer Res. 1990;50:7820-7825.
21. Colombo MP, Ferrari G, Stoppacciaro A, et al. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med. 1991;173:889-897.
22. Porgador A, Tzehoval E, Katz A, et al. Interleukin-6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 1992;52:3679-3686.
23. + T cell-dependent tumor rejection. J Exp Med. 1991;174:1291-1298.
24. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539-3543.
25. Caruso M, Pham-Nguyen K, Kwong YL, et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA. 1996;93:11302-11306.
26. Chen SH, Chen XH, Wang Y, et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA. 1995;92:2577-2581.
27. O'Malley BW Jr, Cope KA, Chen SH, Li D, Schwarta MR, Woo SL. Combination gene therapy for oral cancer in a murine model. Cancer Res. 1996;56:1737-1741.
28. Chen SH, Kosai K, Xu B, et al. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res. 1996;56:3758-3762.
29. Santodonanto L, D'Agostino G, Santini SM, et al. Local and systemic antitumor response after combined therapy of mouse metastatic tumors with tumor cells expressing B IFN-α and HSVtk: perspectives for the generation of cancer vaccines. Gene Ther. 1997;4:1246-1255.
30. Kremer EJ, Perricaudet M. Adenovirus and adeno-associated virus-mediated gene transfer. Br Med Bull. 1995;51: 31-44.
31. Descamps V, Duffour MT, Mathieu MC, et al. Strategies for cancer gene therapy using adenoviral vectors. J Mol Med. 1996-74:183-189.
32. Mittal SK, Belt AJ, Prevec L, Graham FL. Foreign gene expression by human adenovirus type 5-based vectors studied using firefly luciferase and bacterial β galactosidase genes as reporters. Virology. 1995;210:226-230.
33. Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA. 1994;91:6196-6200.
34. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992;52:1399-1405.
35. Coveney E, Clary B, Iacobucci M, Philip R, Lyerly K. Active immunotherapy with transiently transfected cytokine-secreting tumor cells inhibits breast cancer metastases in tumor-bearing animals. Surgery. 1996;120: 265-272.
36. Arai K, Lee F, Miyajima A, Miyatake S, Arai N, Yokota T. Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem. 1990;59:783-836.
37. Crouzet J, Naudin L, Orsini C, et al. Recombinational construction in Escherichia coli of infectious adenoviral genomes. Proc Natl Acad Sci USA. 1997;94:1414-1419.
38. Jung R, Schauer U, Heusser C, Neumann C, Rieger C. Detection of intracellular cytokines by flow cytometry. J Immunol Methods. 1993;159:197-207.
39. Kwong YL, Chen SH, Kosai K, Finegold MJ, Woo SL. Adenoviral-mediated suicide gene therapy for hepatic metastases of breast cancer. Cancer Gene Ther. 1996;3: 339-344.
40. Blankenstein T, Qin ZH, Uberla K, et al. Tumor suppression after tumor cell-targeted tumor necrosis factor-α gene transfer. J Exp Med. 1991;173:1047-1052.
41. Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 1998;58:1486-1493.
42. Bonnekoh B, Greenhalgh DA, Chen SH, et al. Ex vivo and in vivo adenovirus-mediated gene therapy strategies induce a systemic anti-tumor immune defense in the B16 melanoma model. J Invest Dermatol. 1998;110:867-871.